Teaming up for innovative solutions
How does a pharmaceutical leader like Bristol-Myers Squibb (BMS) deliver viable solutions to help meet the challenges of Alzheimer’s, diabetes, hepatitis, HIV/AIDS, cancer and many of society’s other clinical needs?
One way is by keeping pace with the highest standards of manufacturing technology to support its product development pipeline. Most recently, this was reinforced by a facilities redesign initiative to combine early and late phase cGMP clinical manufacturing and development scale-up at the company’s new Pharmaceutical Development Center of Excellence R&D site in New Brunswick, New Jersey.
As part of that evolution, BMS launched its Clinical Supplies Manufacturing and Drug Product Technology Expansion Project, earning it the 2008 ISPE, Interphex, Pharmaceutical Processing Facility of the Year Award (FOYA) for Equipment Innovation.
Dual–phased approach
The BMS team of corporate and third-party planning, design and construction specialists followed a phased approach to the project, with a goal of creating a flexible facility for multi-product clinical scale manufacturing and processing of solvent–based and potent compound products.
Under Phase I, a 93,000 square foot Clinical Supply Operations (CSO) facility was created to support three key manufacturing functions: a parenteral area equipped with an isolated vial filling line to satisfy sterility and containment requirements; a second zone dedicated to handling OSD products within Active Pharmaceutical Ingredients (API) bands one through four; and a third facility for OSD band five drugs.
In addition, to help ensure product integrity and operator safety, the facility supports full containment for expanded Oral Solid Dose (OSD) operations, incorporating what has been described as the most flexible continuous barrier line in the United States. The new CSO complex is capable of processing oral solid dose batches of up to 400 kilograms and parenteral liquid-fill batches of up to 250 liters.
Phase II of the BMS project called for approximately 39,000 square feet of expanded capabilities to supplement existing OSD operations, and housed a new stand-alone Product Technology Center (PTC) for product development and scale-up. Typical PTC batch sizes can range from 20 kilograms to 100 kilograms. This facility is also designed to handle API band one through four operations.
Expanded oral solid dose operations allow BMS to manufacture Long Term Stability batches to aid in product scale-up and technical transfer to commercial manufacturing sites with batch sizes at least one-tenth of commercial scale.
The Product Technology Center is the first clinical facility to utilize continuous process sterile isolators, representing a significant advancement in integrating technology into drug development.
Collaboration a key to success
The need to coordinate and manage multiple disciplines was a key element of the BMS expansion project. Flexible, adaptable design, critical construction scheduling and tight budget management were imperative to the project’s success.
To accomplish a project of this magnitude, BMS called upon unique process and facilities engineering and construction talent. For project design development, master planning, construction documentation and administrative services, the company turned to IPS Incorporated, Lafayette Hill, Pennsylvania, a leader in the design of pharmaceutical manufacturing facilities.
In addition to the Facility of the Year Award, BMS was recognized with federal and state government health and safety awards throughout the project. Included among these was the OSHA Voluntary Protection Program Star Demonstration Site award for outstanding safety and health management.
Enhanced speed–to–market is among the many benefits BMS expects to derive from its new facilities. But increased capacity and technical innovation will also help the company meet vital future pharmaceutical development and pipeline needs of medical service providers and patients worldwide.
One way is by keeping pace with the highest standards of manufacturing technology to support its product development pipeline. Most recently, this was reinforced by a facilities redesign initiative to combine early and late phase cGMP clinical manufacturing and development scale-up at the company’s new Pharmaceutical Development Center of Excellence R&D site in New Brunswick, New Jersey.
As part of that evolution, BMS launched its Clinical Supplies Manufacturing and Drug Product Technology Expansion Project, earning it the 2008 ISPE, Interphex, Pharmaceutical Processing Facility of the Year Award (FOYA) for Equipment Innovation.
Dual–phased approach
The BMS team of corporate and third-party planning, design and construction specialists followed a phased approach to the project, with a goal of creating a flexible facility for multi-product clinical scale manufacturing and processing of solvent–based and potent compound products.
Under Phase I, a 93,000 square foot Clinical Supply Operations (CSO) facility was created to support three key manufacturing functions: a parenteral area equipped with an isolated vial filling line to satisfy sterility and containment requirements; a second zone dedicated to handling OSD products within Active Pharmaceutical Ingredients (API) bands one through four; and a third facility for OSD band five drugs.
In addition, to help ensure product integrity and operator safety, the facility supports full containment for expanded Oral Solid Dose (OSD) operations, incorporating what has been described as the most flexible continuous barrier line in the United States. The new CSO complex is capable of processing oral solid dose batches of up to 400 kilograms and parenteral liquid-fill batches of up to 250 liters.
Phase II of the BMS project called for approximately 39,000 square feet of expanded capabilities to supplement existing OSD operations, and housed a new stand-alone Product Technology Center (PTC) for product development and scale-up. Typical PTC batch sizes can range from 20 kilograms to 100 kilograms. This facility is also designed to handle API band one through four operations.
Expanded oral solid dose operations allow BMS to manufacture Long Term Stability batches to aid in product scale-up and technical transfer to commercial manufacturing sites with batch sizes at least one-tenth of commercial scale.
The Product Technology Center is the first clinical facility to utilize continuous process sterile isolators, representing a significant advancement in integrating technology into drug development.
Collaboration a key to success
The need to coordinate and manage multiple disciplines was a key element of the BMS expansion project. Flexible, adaptable design, critical construction scheduling and tight budget management were imperative to the project’s success.
To accomplish a project of this magnitude, BMS called upon unique process and facilities engineering and construction talent. For project design development, master planning, construction documentation and administrative services, the company turned to IPS Incorporated, Lafayette Hill, Pennsylvania, a leader in the design of pharmaceutical manufacturing facilities.
In addition to the Facility of the Year Award, BMS was recognized with federal and state government health and safety awards throughout the project. Included among these was the OSHA Voluntary Protection Program Star Demonstration Site award for outstanding safety and health management.
Enhanced speed–to–market is among the many benefits BMS expects to derive from its new facilities. But increased capacity and technical innovation will also help the company meet vital future pharmaceutical development and pipeline needs of medical service providers and patients worldwide.
Labels: Awards, Design/Build


